Portola Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update PTLA Reports Q2 Loss   Portola Pharmaceuticals Inc.® (Nasdaq:(PTLA) today reported financial results and provided a corporate update for the quarter ended June 30, 2017. “FDA approval of our first product, Bevyxxa®, in the second quarter marked the ultimate milestone for Portola and the millions
Complete Reading

Brookfield Asset Management +2.6% after Q2 results BAM Reports Q2 Funds Q2 FFO of $1.026B or $1.01 per share vs. $637M and $0.62 a year ago. Excluding realized disposition gains, FFO from operating activities of $562M was up 9% from $514M a year ago. Those disposition gains were helped by the sale of the company’s
Complete Reading

Puma Biotechnology Reports Second Quarter 2017 Financial Results Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2017. Unless otherwise stated, all comparisons are for the second quarter and six months ended June 30, 2017, compared to the second quarter and six months ended June 30, 2016.
Complete Reading

PIERIS PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2017 AND PROVIDES CORPORATE UPDATE Download PDF PRESS RELEASE PIERIS PHARMACEUTICALS (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, today reported financial results for the second quarter of 2017 and provided an update
Complete Reading

CRUDE OIL PRICES EASE IN ASIA AFTER API REPORTS BUILD, EIA DATA AHEAD COMMODITY TRADERS  CRUDE OIL PRICES EASE in Asia on Wednesday after industry estimates showed US crude supplies gained at the end of last week, though official data is awaited for confirmation. On the New York Mercantile Exchange crude futures for September delivery
Complete Reading

Create Account



Log In Your Account